Bruker collaborates with Utrecht University on mass spectrometry methods
Crosslinking mass spectrometry (XL-MS) can leverage the PhoX Crosslinker and TIMS/PASEF methods with the large-scale use of accurate collision cross sections
Crosslinking mass spectrometry (XL-MS) can leverage the PhoX Crosslinker and TIMS/PASEF methods with the large-scale use of accurate collision cross sections
The new reagent kits aim to make whole genome sequencing more accessible and affordable for labs of all sizes
This powerful new solution aims to provide more accurate COVID-19 antibody detection
Join us on Tuesday, August 11, to learn about a novel serological platform used for COVID-19 testing
Join us on Monday, August 17, to discover solutions for your laboratory's SARS-CoV-2 testing
Vanderbilt researchers use high-throughput data collection, analysis, and visualization to help understand synergy in therapeutic antibody cocktails
The new Arc HPLC System from Waters is exciting QC scientists with its promise of enhanced performance and effortless modernization from any HPLC legacy models
Join us on Wednesday, August 26, to learn about an alternative assay that aims to identify virus-neutralizing antibodies in as little as five hours
BLENREP is the fifth major medicine approval for GSK in 2020
The range of high quality deep well plates are suited for researchers working in molecular biology, cell biology or drug discovery applications
Just leave a quick lab product review today for your chance to scoop one of our weekly $100 prizes
With this numerical result expressed as index value, clinicians will be better equipped to evaluate the duration and level of an individual’s immune response
Exclusive interviews, new methods, free downloads, and much more to help you advance your work
Post-menopausal women with lower levels of the female sex hormone estrogen appear to be at higher risk of developing serious complications of COVID-19
Flow cytometry innovator embraces full solutions approach with focus on entire emission spectra
Dr. Nallasivam Palanisamy, Henry Ford Cancer Institute, discusses his discovery of the first pseudogene-associated recurrent gene fusion in cancer and the potential for this robust biomarker for application beyond prostate cancer
Watch this on-demand webinar to discover how pancreatic cancer-derived organoids can be used as a predictive tool for personalized medicine